| Grant ID | DP250157 |
| Awarded On | November 20, 2024 |
| Title | Clinical Utility Study for the Commercial Launch of a Best-in-Class Liver Cancer Screening Blood Test for High-Risk Liver Disease Patients |
| Program | Product Development Research |
| Award Mechanism | Texas Diagnostic and Devices Company Awards for Product Development Research |
| Institution/Organization | Curve Biosciences |
| Principal Investigator/Program Director | Ritish Patnaik |
| Cancer Sites | Gallbladder, Liver and Intrahepatic Bile Duct |
| Contracted Amount |
$11,340,000* *Pending contract negotiation |
| Lay Summary |
Liver cancer will be the third leading cause of cancer-related death in the United States by 2030 with 90% of these cancers being detected in high-risk liver disease patients. Only one in three liver cancers are found early because the standard-of-care for testing high-risk patients requires multiple doctor appointments and still has difficulty identifying small cancers. Curve Biosciences has created a breakthrough blood test for liver cancer because the national obesity epidemic is leading more people to develop liver disease and eventually liver cancer. This trend is especially a problem in Texas, which ranks 12th worst nationally with an obesity rate of 36%. Curve's blood test identifies ... |